LGHT - ETF AI Analysis
Top Page
Langar Global HealthTech ETF (LGHT)
Rating:68Neutral
Price Target:―
Positive Factors
Standout Winner in Top Holdings
One of the largest positions has delivered very strong gains this year, helping offset weakness in other stocks.
Focused HealthTech Exposure
The ETF concentrates on health technology companies, giving investors targeted access to a specialized growth area within health care.
Mix of Both U.S. and International Names
While the fund is mostly U.S.-based, it still includes a few international health technology companies, adding a bit of geographic variety to the portfolio.
Negative Factors
Weak Recent Performance
The ETF has delivered negative returns so far this year and over the last few months, showing recent performance has been under pressure.
High Concentration in a Few Stocks
A small number of holdings make up a large share of the portfolio, which increases the impact if any of those companies struggle.
Expensive for an ETF
The fund’s expense ratio is relatively high, meaning more of any gains are eaten up by fees compared with lower-cost ETFs.
LGHT vs. SPDR S&P 500 ETF (SPY)
AUM2.37M
RegionGlobal
Expense Ratio0.85%
Beta0.94
IssuerLangar
Inception DateJan 10, 2024
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume446
30 Day Avg. Volume4,268
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
10.27Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering28
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LGHT Summary
The Langar Global HealthTech ETF (LGHT) invests in companies using technology to improve healthcare, rather than tracking a traditional index. It focuses on areas like digital health, telemedicine, biotech tools, and medical devices. Well-known holdings include Intuitive Surgical, which makes robotic surgery systems, and Moderna, known for its vaccines. Someone might invest in this ETF to seek long-term growth from advances in healthcare technology while getting diversification across many health-tech companies. A key risk is that it is heavily concentrated in the healthcare technology sector, so its price can swing more than the overall market.
How much will it cost me?The Langar Global HealthTech ETF (LGHT) has an expense ratio of 0.85%, meaning you’ll pay $8.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized healthcare technology companies rather than tracking a broad index.
What would affect this ETF?The Langar Global HealthTech ETF could benefit from growing demand for innovative healthcare solutions, such as telemedicine and advanced medical devices, driven by aging populations and technological advancements. However, it may face challenges from regulatory changes in healthcare, fluctuating global economic conditions, and potential competition within the health tech sector. Its global exposure and focus on leading companies like Intuitive Surgical and Siemens Healthineers position it well for long-term growth but also make it sensitive to international market volatility.
LGHT Top 10 Holdings
LGHT is heavily tilted toward health care tech, with big positions in surgical robotics, medical devices, and digital platforms, and a truly global footprint. Intuitive Surgical and GE Healthcare have been losing altitude lately, weighing on returns, while ResMed and Veeva are also treading water rather than powering ahead. On the brighter side, Moderna has been a surprising bright spot, and Dexcom’s steady climb helps offset some of the drag. Overall, the fund is concentrated in a few heavyweight names, so their mood swings largely set the tone.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Intuitive Surgical | 12.64% | $299.30K | $150.39B | -25.49% | 78 Outperform | |
| Resmed | 10.71% | $253.56K | $27.64B | -23.60% | 76 Outperform | |
| Veeva Systems | 8.28% | $196.21K | $28.45B | -32.29% | 66 Neutral | |
| GE Healthcare Technologies Inc | 7.38% | $174.78K | $28.36B | -10.63% | 78 Outperform | |
| IQVIA Holdings | 6.71% | $158.98K | $30.41B | 34.31% | 73 Outperform | |
| Moderna | 6.45% | $152.73K | $18.72B | 70.28% | 59 Neutral | |
| Koninklijke Philips | 6.17% | $146.13K | $25.33B | 14.34% | 50 Neutral | |
| Insulet | 6.02% | $142.50K | $10.04B | -54.42% | 70 Outperform | |
| Dexcom | 5.17% | $122.56K | $28.45B | -12.44% | 79 Outperform | |
| Zimmer Biomet Holdings | 4.20% | $99.36K | $15.93B | -8.97% | 73 Outperform |
LGHT Technical Analysis
Negative
―
Price Trends
8.46
Negative
9.07
Negative
9.63
Negative
Market Momentum
-0.11
Negative
37.50
Neutral
28.17
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For LGHT, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 8.16, equal to the 50-day MA of 8.46, and equal to the 200-day MA of 9.63, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 37.50 is Neutral, neither overbought nor oversold. The STOCH value of 28.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LGHT.
LGHT Peer Comparison
Comparison Results
Performance Comparison
LGHT
Langar Global HealthTech ETF
8.00
-2.35
-22.71%
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
GDOC
Goldman Sachs Future Health Care Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents